A venture capital firm with multiple offices throughout Europe recently raised a new fund of EUR 80 million in 2019, and invests alongside a network of over 200 private investors across several industries including the Life Sciences. The firm and its investors typically co-invest with other institutional investors for Life Science investments. The firm prefers to invest in later rounds where no further dilution will occur before an exit. The firm and its network typically allocate €1-5M (in equity/convertible loan) over the life of an investment. Normally each investor in the firm’s network invests between €50K and €2M. The firm primarily invests in companies that are based in the D-A-CH region where the firm has a strong footprint, but will consider compelling opportunities globally. The firm is actively seeking new investment opportunities.

The firm makes highly selective investments in medical devices, diagnostics and in enabling technologies in the biotech sector, including genomic and proteomic sequencing. The firm is currently more interested in diabetes, CNS, and oncology but is generally open to all indications. For medical devices, the firm looks for devices that have some proof-of-concept and is agnostic in terms of technology types.

The firm prefers to co-invest with other institutional Life Science investors, particularly for opportunities outside the D-A-CH region; it is preferred that companies based elsewhere have a lead investor in place before approaching the firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading independent venture capital firm in Western Europe provides private equity financing to early- and mid-stage human healthcare and life science companies. The firm has raised two funds, and generally allocates $4-7M (in equity) per company, always co-investing with other specialized investors and during the whole life of the investment. The firm is currently prioritizing opportunities in Europe.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture firm founded in 2008 with multiple offices in China has a total fund size of $5 Billion USD. The firm is interested in companies raising seed/angel to Series A rounds and provides investments that can range up to $50M depending on the opportunity. Series B round will also be considered occasionally in terms of the potentiality. The firm seeks opportunities globally, though it has a preference for companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital arm of a leading global insurance company headquartered in Western Europe will generally allocate $1-5M for up to 20% equity stake, and selectively does convertible financing as well. The firm does not invest strictly for financial returns and seeks a strategic relationship with the companies they invest in. The firm  will typically participate in Series A and B rounds. The firm anticipates 4-5 investments per year, although this number is subject to fluctuate depending on deal flow. The firm will invest in technologies that will impact regions where the firm has a footprint.

In the life sciences space, the firm seeks innovative technologies that can disrupt and transform the future of insurance. The firm will not consider therapeutics or biopharma opportunities. Any technology with implications to the insurance industry will be considered, including smart diagnostics, genomics, etc. Previously, the firm has expressed interest in technology that helps with chronic disease management and considered telemedicine companies as well. In terms of diagnostics, the firm expects the technology to be undergoing promising clinical trials that contribute to its validation. For companies that fall into the digital health sector, the firm expects some ongoing traction and key partnerships to be in place.

The firm seeks to work with companies backed by a full management team with strong industry expertise. Ideally, the team will have a strong life sciences background and an experienced advisory team, with good understanding of how their product or technology works. The firm can act as the lead or co-investor and will most likely take a board seat if they were to lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 is focused on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. Currently, the firm is partnered with the Chinese Government to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also interested in medical devices focusing on large disease areas within China such as diabetes and cancer. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large pharmaceutical company with multiple offices globally is actively seeking partnering and in-licensing opportunities across all developmental stages globally.

The firm’s core commercial expertise and partnering interests are primarily in the hospital care areas. The firm is looking for collaboration in oncology (in therapeutics and diagnostics), autoimmune/inflammatory diseases, novel antibacterial products and diagnostics (particularly in application to Gram-negative organisms), anti-viral, anti-fungal therapeutics, diagnostics for acute hospital care, rare/orphan disease areas, and cell therapies. The firm is seeking to in-license early-stage assets from pre-clinical to Phase I. However, with rare and orphan disease therapeutics, the company will prefer later-stage clinical assets.

The firm seeks to work with companies developing innovative therapeutics and management teams with strong scientific expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A wholly-owned subsidiary of a pharmaceutical and chemical company headquartered in Seoul, South Korea with offices in the USA is actively seeking promising compounds for innovative new drugs that have global market potential. The firm seeks to partner with companies in a wide variety of ways, including licensing, equity investment, joint venture development, etc. depending on the opportunity and strategic fit. The firm is focused on USA-based opportunities.

The firm is focused only on therapeutics, and does not invest in devices, diagnostics, or digital health companies. The firm is most interested in first-in-class (or best-in-class) assets in oncology/immuno-oncology, NASH and other metabolic diseases. The firm is focused on early-stage opportunities, and prefers to invest equity into partnered companies for R&D collaboration.

The firm does not have specific management team requirements and is open to working with all types of management teams. The firm can either lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.